A Phase III, Randomized, Double-masked, Placebo-controlled, Parallel-group, Multicenter Study of the Safety and Efficacy of OT-101 (Atropine Sulfate 0.01%) in Treating the Progression of Myopia in Pediatric Subjects
Latest Information Update: 15 Jul 2024
At a glance
- Drugs Atropine (Primary)
- Indications Myopia
- Focus Registrational; Therapeutic Use
- Sponsors Ocumension Therapeutics
- 07 Aug 2023 Status changed from recruiting to active, no longer recruiting.
- 19 Sep 2022 Planned End Date changed from 1 May 2026 to 1 Apr 2027.
- 19 Sep 2022 Planned primary completion date changed from 1 Apr 2026 to 1 Mar 2027.